Jim Simons Kronos Bio, Inc. Transaction History

Renaissance Technologies LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	SELL	$0.82 - $1.07 $56,975 - $74,345	-69,482 Reduced 5.93%	1,102,326 $903,000
Q4 2024 Feb 13, 2025	BUY	$0.82 - $1.07 $158,058 - $206,246	192,754 Added 19.69%	1,171,808 $1.11 Million
Q3 2024 Nov 13, 2024	BUY	$0.92 - $1.5 $197,733 - $322,392	214,928 Added 28.13%	979,054 $979,000
Q2 2024 Aug 09, 2024	SELL	$0.73 - $1.38 $195,204 - $369,017	-267,404 Reduced 25.92%	764,126 $947,000
Q1 2024 May 13, 2024	BUY	$1.02 - $1.3 $120,976 - $154,185	118,604 Added 12.99%	1,031,530 $1.34 Million

Q4 2023 Feb 13, 2024	SELL	$0.75 - $1.49 $66,580 - $132,273	-88,774 Reduced 8.86%	912,926 $1.14 Million
Q3 2023 Nov 14, 2023	SELL	$1.23 - $2.25 $240,588 - $440,100	-195,600 Reduced 16.34%	1,001,700 $1.3 Million
Q2 2023 Aug 11, 2023	BUY	$1.24 - $1.92 $337,776 - $523,008	272,400 Added 29.45%	1,197,300 $2.06 Million
Q1 2023 May 12, 2023	BUY	$1.34 - $2.62 $102,644 - $200,692	76,600 Added 9.03%	924,900 $1.35 Million
Q4 2022 Feb 13, 2023	BUY	$1.44 - $3.44 $219,309 - $523,905	152,298 Added 21.88%	848,300 $1.37 Million
Q3 2022 Nov 14, 2022	SELL	$3.35 - $5.55 $358,108 - $593,283	-106,898 Reduced 13.31%	696,002 $2.33 Million
Q2 2022 Aug 12, 2022	BUY	$3.12 - $7.52 $1.91 Million - $4.6 Million	612,145 Added 320.91%	802,900 $2.92 Million
Q1 2022 May 13, 2022	BUY	$6.26 - $14.42 $1.1 Million - $2.53 Million	175,255 Added 1130.68%	190,755 $1.38 Million
Q4 2021 Feb 11, 2022	BUY	$11.35 - $21.18 $175,925 - $328,290	15,500 New	15,500 $211,000

886K

Ticker KRON
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,769,100
Market Cap $50M
Description
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.